Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b/3 study

被引：0
|
作者：
Goadsby, P. J. [1 ]
Dodick, D. W. [2 ]
Ailani, J. [3 ]
Trugman, J. M. [4 ]
Finnegan, M. [4 ]
Lakkis, H. [4 ]
Lu, K. [4 ]
Szegedi, A. [4 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[2] Mayo Clin, Phoenix, AZ USA
[3] Medstar Georgetown Univ Hosp, Washington, DC USA
[4] Allergan Plc, Madison, NJ USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO3117
引用
收藏
页码：811 / 811
页数：1
相关论文
共 50 条
  • [41] Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN)
    Barratt, Jonathan
    Barbour, Sean
    Brenner, Robert M.
    Cooper, Kerry
    Wei Xuelian
    Eren, Necmi
    Floege, Juergen
    Jha, Vivekanand
    Kim, Sung Gyun
    Maes, Bart D.
    Phoon, Richard K. S.
    Singh, Harmeet
    Tesar, Vladimir
    Lafayette, Richard A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [42] Time to Onset of Linaclotide Effect On the Bowel Habits in Patients with Chronic Constipation: Results from a Phase 2B Study
    Johnston, Jeffrey M.
    Lavins, Bernard J.
    MacDougall, James E.
    Lembo, Anthony J.
    Schneier, Harvey
    Shiff, Steven J.
    Kurtz, Caroline B.
    Currie, Mark G.
    GASTROENTEROLOGY, 2009, 136 (05) : A537 - A537
  • [43] Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
    Sandborn, William J.
    Danese, Silvio
    Leszczyszyn, Jaroslaw
    Romatowski, Jacek
    Altintas, Engin
    Peeva, Elena
    Hassan-Zahraee, Mina
    Vincent, Michael S.
    Reddy, Padmalatha S.
    Banfield, Christopher
    Salganik, Mikhail
    Banerjee, Anindita
    Gale, Jeremy D.
    Hung, Kenneth E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2616 - 2628
  • [44] Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
    Anstee, Quentin M.
    Lucas, Kathryn J.
    Francque, Sven
    Abdelmalek, Manal F.
    Sanyal, Arun J.
    Ratziu, Vlad
    Gadano, Adrian C.
    Rinella, Mary
    Charlton, Michael
    Loomba, Rohit
    Mena, Edward
    Schattenberg, Joern M.
    Noureddin, Mazen
    Lazas, Donald
    Goh, George B. B.
    Sarin, Shiv K.
    Yilmaz, Yusuf
    Martic, Miljen
    Stringer, Rowan
    Kochuparampil, Jossy
    Chen, Li
    Rodriguez-Araujo, Gerardo
    Chng, Elaine
    Naoumov, Nikolai V.
    Brass, Clifford
    Pedrosa, Marcos C.
    HEPATOLOGY, 2023, 78 (04) : 1223 - 1239
  • [45] Patients' Experience of Parkinson's Disease Following Treatment with Inhaled Levodopa: Results from a Phase 2b Study
    LeWitt, Peter
    Niyazov, Alexander
    Sedkov, Alexander
    Murck, Harald
    Guo, Amy
    NEUROLOGY, 2016, 86
  • [46] Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts
    Gilbert, Peter B.
    STATISTICS IN MEDICINE, 2010, 29 (10) : 1061 - 1071
  • [47] Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
    Hartung, Hans-Peter
    Derfuss, Tobias
    Cree, Bruce A. C.
    Sormani, Maria Pia
    Selmaj, Krzysztof
    Stutters, Jonathan
    Prados, Ferran
    MacManus, David
    Schneble, Hans-Martin
    Lambert, Estelle
    Porchet, Herve
    Glanzman, Robert
    Warne, David
    Curtin, Francois
    Kornmann, Gabrielle
    Buffet, Benedicte
    Kremer, David
    Kury, Patrick
    Leppert, David
    Ruckle, Thomas
    Barkhof, Frederik
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (03) : 429 - 440
  • [48] EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL
    Ashina, M.
    Goadsby, P. J.
    Lipton, R. B.
    Azimova, J.
    Winner, P.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    CEPHALALGIA, 2018, 38 : 84 - 85
  • [49] HVTN100 phase 1/2 vaccine trial results promising; phase 2b/3 trial to commence
    Harper, Kristin N.
    AIDS, 2017, 31 (02) : N1 - N2
  • [50] Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs
    Ruppert, Amy S.
    Shoben, Abigail B.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 12 : 40 - 50
12345